阿达木单抗治疗的银屑病关节炎患者皮肤与关节受累之间的关联：来自一项德国非干预性研究的数据分析
Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study.
作者信息
Thaçi Diamant, Behrens Frank, Greger Gerd, Burkhardt Harald, Gnann Holger, Schopf Rudolf, Wittig Bianca Maria
机构信息
Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
出版信息
Dermatology. 2015;230(3):213-21. doi: 10.1159/000371546. Epub 2015 Jan 27.
BACKGROUND
The association between skin and joint manifestations in patients with psoriatic arthritis (PsA) requires further characterization.
OBJECTIVE
We evaluated the association between severity of skin disease and joint involvement and the effectiveness and safety of adalimumab in PsA patients by baseline psoriasis severity.
METHODS
Descriptive statistics and regression analyses were used to evaluate data from 1,918 PsA patients starting adalimumab treatment. Subgroup analyses were conducted on patients empirically grouped by baseline target lesion score as a marker of psoriasis severity.
RESULTS
Psoriasis severity was not associated with joint manifestations at baseline or after 12 months of treatment. All subgroups showed improvements in skin and joints during therapy, and adalimumab was safe and well tolerated in all subgroups.
CONCLUSION
The severity of skin manifestations does not correlate with the severity of joint disease in PsA patients; even patients with mild skin disease may have extensive musculoskeletal involvement.
背景
银屑病关节炎（PsA）患者皮肤与关节表现之间的关联需要进一步明确。
目的
我们通过基线银屑病严重程度评估了PsA患者皮肤病严重程度与关节受累情况之间的关联，以及阿达木单抗的有效性和安全性。
方法
使用描述性统计和回归分析来评估1918例开始接受阿达木单抗治疗的PsA患者的数据。对根据基线靶皮损评分作为银屑病严重程度标志物进行经验性分组的患者进行亚组分析。
结果
银屑病严重程度与基线时或治疗12个月后的关节表现无关。所有亚组在治疗期间皮肤和关节均有改善，阿达木单抗在所有亚组中均安全且耐受性良好。
结论
PsA患者皮肤表现的严重程度与关节疾病的严重程度不相关；即使是轻度皮肤病患者也可能有广泛的肌肉骨骼受累。
Zotero 插件